Stockscreener 앱 받기
9.36
0.53%
-0.05
시간 외 거래:
9.54
0.18
+1.92%
Zevra Therapeutics Inc 주식(ZVRA)의 최신 뉴스
Analyzing drawdowns of Zevra Therapeutics Inc. with statistical toolsJuly 2025 Momentum & Accurate Technical Buy Alerts - Newser
Is now a turning point for Zevra Therapeutics Inc.Portfolio Risk Summary & Risk Adjusted Swing Trade Ideas - Newser
Full technical analysis of Zevra Therapeutics Inc. stock2025 Key Highlights & Reliable Price Breakout Signals - Newser
Custom strategy builders for tracking Zevra Therapeutics Inc.Weekly Stock Recap & Weekly Breakout Watchlists - Newser
Using data models to predict Zevra Therapeutics Inc. stock movement2025 Breakouts & Breakdowns & Low Drawdown Momentum Ideas - Newser
What makes Zevra Therapeutics Inc. stock price move sharplyQuarterly Growth Report & Capital Efficient Trade Techniques - Newser
Is Zevra Therapeutics Inc. stock overhyped or has real potentialQuarterly Portfolio Review & Free High Return Stock Watch Alerts - Newser
Automated trading signals detected on Zevra Therapeutics Inc.Earnings Overview Report & Low Risk High Win Rate Picks - Newser
How to build a dashboard for Zevra Therapeutics Inc. stock2025 Stock Rankings & Daily Momentum Trading Reports - Newser
Zevra Therapeutics reports Q2 EPS $1.21, consensus $1.38 - MSN
Zevra Therapeutics: Building a Rare Disease Empire Through Strategic Communication and Pipeline Innovation - AInvest
Rare Disease Biotech Zevra Therapeutics Set for Key September Investor Conference Presentations - Stock Titan
Zevra Therapeutics Announces Executive Leadership Team Participation in Upcoming Conferences. - AInvest
Zevra Therapeutics to Participate at Upcoming Investor Conferences in September - GlobeNewswire
Is Zevra Therapeutics Inc. forming a reversal patternVolume Spike & Long-Term Safe Investment Plans - Newser
Real time scanner hits for Zevra Therapeutics Inc. explainedQuarterly Trade Review & Short-Term High Return Strategies - Newser
Is Zevra Therapeutics Inc. still worth holding after the dip2025 Market Overview & Comprehensive Market Scan Insights - Newser
Will earnings trigger a reversal in Zevra Therapeutics Inc.July 2025 Outlook & Short-Term Trading Alerts - Newser
Zevra Therapeutics’ Earnings Call: Optimism Amid Challenges - MSN
What are Zevra Therapeutics Inc.’s earnings expectationsMarket Activity Report & High Accuracy Trade Signal Alerts - theviewers.co.kr
Published on: 2025-08-23 18:47:11 - Newser
Heatmap analysis for Zevra Therapeutics Inc. and competitorsMarket Sentiment Review & Weekly Return Optimization Plans - Newser
Risk adjusted return profile for Zevra Therapeutics Inc. analyzedJuly 2025 Pullbacks & Weekly Chart Analysis and Guides - Newser
Is Zevra Therapeutics Inc. forming a bullish divergenceMarket Volume Summary & AI Powered Market Trend Analysis - theviewers.co.kr
Zevra Therapeutics gains amid takeover speculation - MSN
Zevra Therapeutics stock gains amid takeover speculation (ZVRA:NASDAQ) - Seeking Alpha
ZEVRA THERAPEUTICS Director John B Bode Acquires 5,000 Shares - TradingView
Zevra Therapeutics Faces $58.7 Million Impairment Charge, Raising Concerns Over Financial Stability - MSN
Is Zevra Therapeutics Inc. stock a falling knife or bargain buyWeekly Trading Summary & Capital Efficiency Focused Ideas - newsyoung.net
Institutional Investors in Zevra Therapeutics, Inc. (NASDAQ:ZVRA) Lost 22% Last Week but Have Reaped the Benefits of Longer-term Growth - 富途牛牛
Zevra Therapeutics (ZVRA) Reports Q2 Loss, Tops Revenue Estimates (Revised) - sharewise.com
Zevra signals continued MIPLYFFA momentum with 26% revenue growth and $150M PRV sale strengthening balance sheet - MSN
Zevra Therapeutics Q2 Earnings Top Revenue Estimates, Shares Up 40% YTD - AInvest
Can Zevra Therapeutics Inc. Outperform Peers After Recent PullbackWeekly Stock Recap & Risk Controlled Daily Trade Plans - sundaytimes.kr
How do insiders feel about Zevra Therapeutics Inc.Weekly Trading Summary & Accurate Buy Signal Notifications - thegnnews.com
Zevra Therapeutics’ SWOT analysis: stock soars on MIPLYFFA success, pipeline potential - Investing.com
Zevra Therapeutics (ZVRA) Reports Q2 Loss, Tops Revenue Estimates - MSN
Zevra Therapeutics at Canaccord Conference: Strategic Growth Insights By Investing.com - Investing.com Canada
Zevra Therapeutics Crashes, Reversing 89% Run. Why It Could Be An 'Overreaction.' - inkl
JMP Securities maintains Market Outperform on Zevra, lowers PT to $18. - AInvest
Price Channel Expanding on Zevra Therapeutics Inc.’s ChartShort Setup & Risk Controlled Swing Alerts - sundaytimes.kr
Zevra Therapeutics, Inc. (NASDAQ:ZVRA) Q2 2025 Earnings Call Transcript - Insider Monkey
Zevra Therapeutics: Strong Buy Rating Amid U.S. Growth and EU Market Potential - TipRanks
Zevra Therapeutics price target lowered to $18 from $19 at Citizens JMP - TipRanks
Zevra Therapeutics shares fall 9.01% premarket despite Q2 profit and revenue growth. - AInvest
Zevra Therapeutics stock price target lowered to $18 at Citizens JMP - Investing.com Australia
Zevra Therapeutics stock price target lowered to $18 at Citizens JMP By Investing.com - Investing.com South Africa
0.98%
8.06%
자본화:
|
볼륨(24시간):